Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Outcome of relapse after allogeneic HSCT in children with ALL enrolled in the ALL-SCT 2003/2007 trial

Research output: Contribution to journalJournal articleResearchpeer-review


  1. Declining mortality rates in children admitted to ICU following HCT

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Correction: ABO incompatibile graft management in pediatric transplantation

    Research output: Contribution to journalComment/debateResearchpeer-review

  • Michaela Kuhlen
  • Andre M Willasch
  • Jean-Hugues Dalle
  • Jacek Wachowiak
  • Isaac Yaniv
  • Marianne Ifversen
  • Petr Sedlacek
  • Tayfun Guengoer
  • Peter Lang
  • Peter Bader
  • Sabina Sufliarska
  • Adriana Balduzzi
  • Brigitte Strahm
  • Irene von Luettichau
  • Jessica I Hoell
  • Arndt Borkhardt
  • Thomas Klingebiel
  • Martin Schrappe
  • Arend von Stackelberg
  • Evgenia Glogova
  • Ulrike Poetschger
  • Roland Meisel
  • Christina Peters
View graph of relations

Relapse remains the major cause of treatment failure in children with high-risk acute lymphoblastic leukaemia (ALL) undergoing allogeneic haematopoietic stem-cell transplantation (allo-SCT). Prognosis is considered dismal but data on risk factors and outcome are lacking from prospective studies. We analysed 242 children with recurrence of ALL after first allo-SCT enrolled in the Berlin-Frankfurt-Munster (BFM) ALL-SCT-BFM 2003 and ALL-SCT-BFM international 2007 studies. Median time from allo-SCT to relapse was 7·7 months; median follow-up from relapse after allo-SCT until last follow-up was 3·4 years. The 3-year event-free survival (EFS) was 15% and overall survival (OS) was 20%. The main cause of death was disease progression or relapse (86·5%). The majority of children (48%) received salvage therapy without second allo-SCT, 26% of the children underwent a second allo-SCT and 25% received palliative treatment only. In multivariate analyses, age, site of relapse, time to relapse and type of salvage therapy were identified as significant prognostic factors for OS and EFS, whereas factors associated with first SCT were not statistically significant. Combined approaches incorporating novel immunotherapeutic treatment options and second allo-SCT hold promise to improve outcome in children with post allo-SCT relapse.

Original languageEnglish
JournalBritish Journal of Haematology
Issue number1
Pages (from-to)82-89
Number of pages8
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 52167756